tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Deutsche cut AstraZeneca to Sell on ‘thoroughly underwhelming’ Q4

Deutsche Bank downgraded AstraZeneca to Sell from Hold with a price target of 9,500 GBp, down from 11,000 GBp. The company’s Q4 is a “thoroughly underwhelming end to 2023 with a soft print that missed in most of the places that matter,” the analyst tells investors in a research note. The firm says AstraZeneca’s fiscal 2024 guidance is nominally in-line with expectations while signaling on core margin “is ambiguous.” Deutsche Bank sees “highly negative signaling” and a lack of catalysts for the shares.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on AZN:

Disclaimer & DisclosureReport an Issue

1